series-c-plus
Stage
1
Investors
About
Metavention develops the iRF Denervation System, a minimally invasive radiofrequency-based medical device designed to disrupt overactive renal sympathetic nerves to treat high blood pressure and associated metabolic diseases. The device is currently in clinical studies and remains investigational under US federal law.
Explore Metavention's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.